2010
DOI: 10.1182/blood.v116.21.2807.2807
|View full text |Cite
|
Sign up to set email alerts
|

Ritonavir Based Highly Active Retroviral Therapy (HAART) Correlates with Early Neurotoxicity When Combined with ABVD Treated HIV Associated Hodgkin Lymphoma but Not Non-Hodgkin Lymphoma. A Retrospective Study.

Abstract: 2807 Background: Hodgkin (HL) and non-Hodgkin lymphoma (NHL) are the most common non-HIV-defining and HIV-defining malignancies, respectively1. Patients (pts) treated for lymphoma concomitantly with highly active retroviral therapy (HAART) have much better response rates and overall survival2. However, few studies have assessed the impact of HAART on the adverse events of chemotherapy. The Stanford V regimen for HL has a 48 % increase in neurotoxicity and neu… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
4
0

Year Published

2012
2012
2024
2024

Publication Types

Select...
5

Relationship

2
3

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 0 publications
0
4
0
Order By: Relevance
“…An important aspect of HIV-cHL therapy is the identification of potential cART/chemotherapy interactions. Interactions with chemotherapy have become more pronounced as many cART inhibit or induce CYP450 enzymes or drug transporter like P-glycoprotein which are important mechanisms of drug distribution and excretion [1014]. cART/chemotherapy interactions therefore increase toxicity or potentially decrease efficacy [2,3,1012].…”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations
“…An important aspect of HIV-cHL therapy is the identification of potential cART/chemotherapy interactions. Interactions with chemotherapy have become more pronounced as many cART inhibit or induce CYP450 enzymes or drug transporter like P-glycoprotein which are important mechanisms of drug distribution and excretion [1014]. cART/chemotherapy interactions therefore increase toxicity or potentially decrease efficacy [2,3,1012].…”
Section: Introductionmentioning
confidence: 99%
“…Interactions with chemotherapy have become more pronounced as many cART inhibit or induce CYP450 enzymes or drug transporter like P-glycoprotein which are important mechanisms of drug distribution and excretion [1014]. cART/chemotherapy interactions therefore increase toxicity or potentially decrease efficacy [2,3,1012]. The protease inhibitor ritonavir, a CYP3A4 and P-glycoprotein inhibitor, increases vinblastine-related neuropathy and neutropenia which is a key component of HIV-cHL treatment [2,3,1012].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Another factor that has influenced outcomes in studies of HIV‐related cancers is pharmacokinetic interactions between antiretroviral drugs and chemotherapy. One extreme example is the interaction of ritonavir and vinblastine, which resulted in life‐threatening toxicity with the standard doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) regimen for classic Hodgkin lymphoma . Another less obvious example is the concomitant use of diadnosine with the infusional cyclophosphamide, doxorubicin, and etoposide regimen in HIV‐related non‐Hodgkin lymphoma.…”
mentioning
confidence: 99%